サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794436

吸収不良症候群の世界市場

Malabsorption Syndrome

出版日
ページ情報
英文 185 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
吸収不良症候群の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

吸収不良症候群の世界市場は2030年までに43億米ドルに到達

2024年に35億米ドルと推定される吸収不良症候群の世界市場は、2024年から2030年にかけてCAGR 3.8%で成長し、2030年には43億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである乳糖不耐症の適応症は、CAGR 4.3％を記録し、分析期間終了までに27億米ドルに達すると予想されます。スプルー適応症セグメントの成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は9億4,660万米ドルと推定、中国はCAGR 7.1％で成長すると予測

米国の吸収不良症候群市場は、2024年に9億4,660万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億7,990万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5%と3.0%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の吸収不良症候群市場- 主要動向と促進要因のまとめ

吸収不良症候群が消化器ヘルスケアで注目される理由とは？

吸収不良症候群は、その複雑な症状と患者のQOLに大きな影響を与えることから、消化器医療の分野でますます注目を集めています。この病態は、小腸における脂肪、タンパク質、炭水化物、ビタミン、ミネラルなどの栄養素の吸収不全を指し、多くの場合、正常な食物摂取にもかかわらず栄養失調を引き起こします。セリアック病、クローン病、慢性膵炎、短腸症候群、腸の機能を変化させる特定の感染症や手術など、さまざまな基礎疾患から生じる可能性があります。慢性的な下痢、体重減少、腹部膨満感、疲労、栄養不足などの症状は、一般的な胃腸疾患と誤認されることが多く、適時の診断が困難です。内視鏡検査、便分析、血中栄養素プロファイリングなどの診断ツールの改善と認知度の向上により、臨床医は吸収不良を早期に発見し、的を絞った介入を開始できるようになりました。この症候群はまた、カルシウム、鉄、ビタミンB群の長期的な欠乏に起因する骨粗鬆症、貧血、神経機能障害などの症状を引き起こし、全身に影響を及ぼします。より多くのヘルスケアプロバイダーがこの疾患の多因子性を認識するにつれ、消化器専門医、栄養士、内分泌専門医を含む集学的アプローチが標準となりつつあります。このような幅広い認識が、以前は診断も治療もされなかったかもしれない患者の予後改善に役立っています。先進地域でも開発途上地域でも、吸収不良の原因となる基礎疾患の有病率は増加しており、見過ごされがちなこの症候群の早期発見と管理に、よりしっかりとした臨床的焦点が当てられるようになってきています。

診断と治療の進歩は患者の予後をどのように改善しているか？

診断法と治療戦略における革新は、吸収不良症候群の同定と治療方法を大幅に改善しつつあります。より感度の高いバイオマーカーや非侵襲的な検査の開発により、医師は栄養素の欠乏や消化酵素の活性をより正確に検出できるようになりました。カプセル内視鏡や磁気共鳴腸造影などの高度な画像技術は、小腸を可視化する能力を向上させ、大規模な外科的介入なしに構造的または機能的な異常を検出できるようになりました。セリアック病のような疾患に関連する遺伝子マーカーの分子検査は、特に症状が重複している場合の鑑別診断をさらに合理化しています。治療面では、鉄、葉酸、ビタミンD、脂溶性ビタミンの特定の欠乏に対処する個別の栄養計画が回復の中心的役割を果たしています。酵素補充療法やプロバイオティクスは、特に膵臓機能不全や小腸細菌の過剰増殖に起因する症例において、消化機能と微生物バランスを回復させるために使用されています。重度の腸管障害や不可逆的な腸管障害を有する患者では、長期生存と栄養の適正を確保するために、非経口栄養や腸管移植などの介入が行われています。医薬品の研究も進んでおり、炎症を抑えたり、免疫反応を調節したり、栄養吸収を高めたりすることを目的とした新しい製剤の臨床試験が行われています。これらの進歩は、患者の生活の質を向上させるだけでなく、病院での再入院を減らし、食事プロトコールの遵守を強化し、より良い長期的な疾病管理を促進します。これらの技術や治療が統合されることで、吸収不良症候群は管理困難な疾患から、よりコントロールしやすく診断可能な消化器医療へと変貌を遂げつつあります。

吸収不良の発生率の増加にはどのような疫学的動向と生活様式が関与しているのか？

疫学的およびライフスタイル的要因の組み合わせが、世界の集団における吸収不良症候群の発生率および診断率の上昇に寄与しています。主な要因の1つは、セリアック病や炎症性腸疾患などの自己免疫疾患の有病率の増加であり、これらはいずれも栄養吸収を著しく損ない、スクリーニングや認知度の向上により診断頻度が増加しています。天然酵素や食物繊維の少ない加工食品の摂取増加などの食生活の変化は、消化器の健康を損ない、吸収不良を誘発または悪化させる腸内細菌叢の不均衡を助長すると考えられています。ジアルジア症や熱帯スプルーなどの感染症は、多くの低所得地域で依然として流行しており、特に小児や免疫不全者において、後天性吸収不良の高い割合につながっています。肥満手術や腸切除のような外科的処置の頻度は増加しており、その結果、吸収表面積が減少し、十分な栄養を維持する上で長期的な課題が生じることが多いです。高齢化した集団はまた、慢性膵炎や萎縮性胃炎のような状態に陥りやすく、これらはいずれも消化吸収を損なう可能性があります。世界の多くの地域では、新鮮で栄養豊富な食品やヘルスケアサービスを利用するための社会経済的な障壁が、さらにリスクを高めています。さらに、抗生物質、制酸剤、化学療法剤などの特定の薬剤の使用は、腸の完全性や微生物バランスを乱し、間接的に吸収不良の問題を引き起こす可能性があります。このような要因が重なることで、症状の治療だけでなく、多様な患者集団における吸収不良の根本的な原因を特定し、緩和することに焦点を当てた、プロアクティブなヘルスケア戦略の重要性が強調されています。

世界の吸収不良症候群市場の成長を促進する要因とは？

世界の吸収不良症候群市場の成長は、疾患有病率の上昇、診断能力の向上、治療手法の進化、一般市民や専門家の意識の高まりなど、相互に関連するいくつかの要因によって牽引されています。吸収不良を頻繁に引き起こす胃腸障害や自己免疫疾患の増加により、長期的なケアや栄養管理を必要とする患者層が拡大しています。臨床検査診断と画像診断の進歩により、臨床医は吸収不良の存在と原因を突き止めることが容易になり、その結果、より早く、より正確な介入を行うことができるようになりました。製薬会社および栄養補助食品会社は、酵素サプリメント、腸内細菌叢調整剤、および吸収障害のある患者に合わせた特殊な経腸栄養剤を含む、標的療法の開発に投資しています。慢性消化管疾患に対するヘルスケアへのアクセスと償還の拡大は、特に新興市場において、これまで診断されていなかった症例が正式なヘルスケアシステムに入るようになり、より多くの人々が治療を受けるよう促しています。遠隔医療とデジタルヘルスプラットフォームは、吸収不良患者に対するより広範な教育、フォローアップ、管理を可能にし、合併症の減少と治療レジメンのコンプライアンスの改善に役立っています。病院、研究機関、食品技術企業間のパートナーシップの拡大は、長期的な患者サポートに不可欠な医療用栄養製品のイノベーションを促進しています。さらに、ヘルスケア専門家や一般市民を対象とした教育キャンペーンにより、吸収不良の症状や早期管理の重要性に対する認識が向上しています。こうした複合的な要因が、市場情勢の着実な成長に寄与し、胃腸の健康という広い視野の中で優先的に注目すべき分野としての地位を強化しています。

セグメント

適応症（乳糖不耐症、スプルー症、嚢胞性線維症）

調査対象企業の例

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Chiesi Farmaceutici S.p.A.
  • Digestive Care, Inc.
  • Eli Lilly and Company
  • Allergan plc
  • Horizon Therapeutics plc
  • Johnson & Johnson（Janssen）
  • Mylan/Viatris
  • Nordmark Arzneimittel GmbH & Co.
  • Nestle（Zenpep）
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Protalix BioTherapeutics Inc.
  • Reddy's Laboratories
  • Sanofi（Genzyme）
  • Shire（Takeda）
  • Ultragenyx Pharmaceutical Inc.

AI統合

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37322

Global Malabsorption Syndrome Market to Reach US$4.3 Billion by 2030

The global market for Malabsorption Syndrome estimated at US$3.5 Billion in the year 2024, is expected to reach US$4.3 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Lactose Intolerance Indication, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Sprue Indication segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$946.6 Million While China is Forecast to Grow at 7.1% CAGR

The Malabsorption Syndrome market in the U.S. is estimated at US$946.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$879.9 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Malabsorption Syndrome Market - Key Trends & Drivers Summarized

Why Is Malabsorption Syndrome Gaining Medical Attention in Gastrointestinal Healthcare?

Malabsorption syndrome is garnering increasing attention in the field of gastrointestinal health due to its complex presentation and significant impact on patient quality of life. This condition refers to the inadequate absorption of nutrients such as fats, proteins, carbohydrates, vitamins, and minerals in the small intestine, often resulting in malnutrition despite normal food intake. It can arise from various underlying disorders including celiac disease, Crohn’s disease, chronic pancreatitis, short bowel syndrome, and certain infections or surgeries that alter intestinal function. Symptoms such as chronic diarrhea, weight loss, bloating, fatigue, and nutrient deficiencies are frequently misattributed to more common gastrointestinal ailments, which complicates timely diagnosis. With greater awareness and improved diagnostic tools such as endoscopy, stool analysis, and blood nutrient profiling, clinicians are now better equipped to detect malabsorption earlier and initiate targeted interventions. The syndrome also has systemic implications, contributing to conditions like osteoporosis, anemia, and neurological dysfunction due to long-term deficiencies in calcium, iron, and B vitamins. As more healthcare providers recognize the multifactorial nature of this condition, a multidisciplinary approach involving gastroenterologists, dietitians, and endocrinologists is becoming standard. This broader recognition is helping to improve outcomes for patients who previously might have gone undiagnosed or untreated. In both developed and developing regions, the prevalence of underlying diseases that contribute to malabsorption is increasing, prompting a more robust clinical focus on early identification and management of this often-overlooked syndrome.

How Are Advances in Diagnosis and Treatment Improving Patient Outcomes?

Innovations in diagnostic methods and therapeutic strategies are significantly improving how malabsorption syndrome is identified and treated. The development of more sensitive biomarkers and non-invasive tests is allowing physicians to detect nutrient deficiencies and digestive enzyme activity with greater precision. Advanced imaging technologies such as capsule endoscopy and magnetic resonance enterography have improved the ability to visualize the small intestine and detect structural or functional abnormalities without extensive surgical intervention. Molecular testing for genetic markers associated with conditions like celiac disease is further streamlining differential diagnosis, particularly in cases with overlapping symptoms. On the treatment front, personalized nutrition plans that address specific deficiencies in iron, folate, vitamin D, and fat-soluble vitamins are playing a central role in recovery. Enzyme replacement therapies and probiotics are being used to restore digestive function and microbial balance, especially in cases stemming from pancreatic insufficiency or small intestinal bacterial overgrowth. In patients with severe or irreversible intestinal damage, interventions such as parenteral nutrition or intestinal transplantation are being employed to ensure long-term survival and nutritional adequacy. Pharmaceutical research is also advancing, with new drug formulations aimed at reducing inflammation, modulating immune response, or enhancing nutrient absorption being tested in clinical trials. These advancements are not only improving the quality of life for patients but also reducing hospital readmissions, enhancing adherence to dietary protocols, and fostering better long-term disease management. The integration of these technologies and treatments is transforming malabsorption syndrome from a difficult-to-manage condition into a more controllable and diagnosable aspect of gastrointestinal medicine.

What Epidemiological and Lifestyle Trends Are Contributing to the Rising Incidence of Malabsorption?

A combination of epidemiological and lifestyle factors is contributing to the rising incidence and diagnosis of malabsorption syndrome across global populations. One major factor is the growing prevalence of autoimmune conditions such as celiac disease and inflammatory bowel disease, both of which significantly impair nutrient absorption and are being diagnosed more frequently due to improved screening and awareness. Changes in diet, including increased consumption of processed foods low in natural enzymes and fiber, are believed to compromise digestive health and contribute to imbalances in gut flora that can precipitate or exacerbate malabsorption. Infections such as giardiasis and tropical sprue remain endemic in many low-income regions, leading to high rates of acquired malabsorption, especially in children and immunocompromised individuals. Surgical procedures like bariatric surgery and bowel resections, which are increasing in frequency, often result in a reduced absorptive surface area and create long-term challenges in maintaining adequate nutrition. Aging populations are also more prone to conditions like chronic pancreatitis and atrophic gastritis, both of which can impair digestion and absorption. In many parts of the world, socio-economic barriers to accessing fresh, nutrient-rich foods and healthcare services further compound the risks. Additionally, the use of certain medications such as antibiotics, antacids, and chemotherapy agents can disrupt gut integrity or microbial balance, indirectly triggering malabsorption issues. The convergence of these factors underscores the importance of proactive healthcare strategies that focus not only on treating symptoms but also on identifying and mitigating the root causes of malabsorption in diverse patient populations.

What Factors Are Driving Growth in the Global Malabsorption Syndrome Market?

The growth in the global malabsorption syndrome market is driven by several interrelated factors tied to rising disease prevalence, improved diagnostic capabilities, evolving treatment methodologies, and heightened public and professional awareness. Increasing rates of gastrointestinal and autoimmune disorders that frequently lead to malabsorption are expanding the pool of patients in need of long-term care and nutritional management. Advances in laboratory diagnostics and imaging have made it easier for clinicians to pinpoint the presence and causes of malabsorption, thus driving earlier and more accurate intervention. Pharmaceutical and nutraceutical companies are investing in the development of targeted therapies, including enzyme supplements, gut microbiota modulators, and specialized enteral nutrition products tailored to patients with absorption impairments. The expansion of healthcare access and reimbursement for chronic gastrointestinal care is encouraging more people to seek treatment, especially in emerging markets where previously undiagnosed cases are now entering the formal healthcare system. Telemedicine and digital health platforms are enabling broader education, follow-up, and management of malabsorption patients, helping to reduce complications and improve compliance with treatment regimens. Growing partnerships between hospitals, research institutions, and food technology firms are fostering innovation in medical nutrition products, which are essential for long-term patient support. Furthermore, educational campaigns aimed at healthcare professionals and the general public are improving recognition of malabsorption symptoms and the importance of early management. These combined factors are contributing to steady growth in the malabsorption syndrome market and reinforcing its place as a priority focus area within the broader landscape of gastrointestinal health.

SCOPE OF STUDY:

The report analyzes the Malabsorption Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Lactose Intolerance Indication, Sprue Indication, Cystic Fibrosis Indication)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Chiesi Farmaceutici S.p.A.
  • Digestive Care, Inc.
  • Eli Lilly and Company
  • Allergan plc
  • Horizon Therapeutics plc
  • Johnson & Johnson (Janssen)
  • Mylan / Viatris
  • Nordmark Arzneimittel GmbH & Co.
  • Nestlé (Zenpep)
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Protalix BioTherapeutics Inc.
  • Reddy's Laboratories
  • Sanofi (Genzyme)
  • Shire (Takeda)
  • Ultragenyx Pharmaceutical Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Malabsorption Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Gastrointestinal and Autoimmune Disorders Throws the Spotlight on Malabsorption Syndrome as a Growing Clinical Concern
    • Increased Awareness Among Clinicians and Patients Propels Earlier Diagnosis and Targeted Therapeutic Intervention
    • Here's the Story: Expanding Use of Genetic and Serological Testing Strengthens the Business Case for Precision Diagnosis of Malabsorption Subtypes
    • Growth in Celiac Disease, Crohn's Disease, and Pancreatic Insufficiency Drives Demand for Disease-Specific Treatment Protocols
    • Here's How Advancements in Nutritional Genomics and Microbiome Research Are Informing Personalized Dietary Management
    • Expansion of Diagnostic Imaging and Endoscopy Improves Detection of Structural and Functional Intestinal Abnormalities
    • Rising Focus on Pediatric and Geriatric Populations Spurs Demand for Tailored Malabsorption Management Strategies
    • Here's How Functional Foods and Medical Nutrition Products Are Supporting Long-Term Symptom Control and Nutrient Repletion
    • Innovation in Enzyme Replacement Therapies and Immunomodulators Fuels Development in Targeted Pharmaceutical Approaches
    • Growth in At-Home Testing and Digital Health Platforms Enhances Monitoring and Patient Engagement for Chronic Cases
    • Here's How Malabsorption Is Increasingly Recognized as a Comorbidity in Metabolic, Oncological, and Infectious Diseases
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Malabsorption Syndrome Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Malabsorption Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lactose Intolerance Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lactose Intolerance Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lactose Intolerance Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sprue Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Sprue Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Sprue Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cystic Fibrosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cystic Fibrosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cystic Fibrosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • JAPAN
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • CHINA
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: China 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • EUROPE
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Malabsorption Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • FRANCE
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: France 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • GERMANY
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Malabsorption Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • INDIA
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: India 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Malabsorption Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Malabsorption Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Malabsorption Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Malabsorption Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030
  • AFRICA
    • Malabsorption Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Malabsorption Syndrome by Indication - Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Malabsorption Syndrome by Indication - Percentage Breakdown of Value Sales for Lactose Intolerance Indication, Sprue Indication and Cystic Fibrosis Indication for the Years 2014, 2025 & 2030

IV. COMPETITION